Anthracycline‑induced cardiotoxicity in the chemotherapy treatment of breast cancer: Preventive strategies and treatment (Review)

• Published in: Molecular and clinical oncology Vol. 11; no. 1; pp. 15 - 23
• Main Authors: Cai, Fengfeng, Luis, Manuel, Lin, Xiaoyan, Wang, Minghong, Cai, Lu, Cen, Chunmei, Biskup, Ewelina
• Format: Journal Article
• Language: English
• Published: England Spandidos Publications 01.07.2019; Spandidos Publications UK Ltd; D.A. Spandidos
• Subjects: Anopheles; Anthracyclines; Apoptosis; Breast cancer; Cancer therapies; Cancer treatment; Cardiac arrhythmia; Cardiology; Cardiomyocytes; Cardiomyopathy; Cardiovascular disease; Cell cycle; Chemotherapy; Coronary vessels; Cyclin-dependent kinases; Development and progression; Disease prevention; Drug therapy; Drugs; Endocrine therapy; Etiology (Medicine); Free radicals; Gene expression; Health; Health aspects; Health screening; Heart failure; Metabolism; Metabolites; Oncology; Oxidative stress; Patients; Radiation therapy; Review; Thrombosis; Tumors; Vincristine; Women; Women's health; Womens health; United States > US; treatment; cardiotoxicity; risk factors; breast cancer; anthracyclines; doxorubicin; prevention
• ISSN: 2049-9450; 2049-9469
• DOI: 10.3892/mco.2019.1854

Anthracyclines are highly effective chemotherapeutic agents, used for a wide variety of malignancies. Cardiotoxicity is a well-recognized side effect of anthracycline therapy that limits the total amount of drug administered and can cause heart failure in some patients. Most experimental data support oxidative stress as the etiology of anthracycline-induced cardiotoxicity. The objective of this paper was to provide a review of the clinical classification, risk factors, monitoring and prevention of anthracycline-induced cardiotoxicity in patients with breast cancer.